Schedule 13G ownership disclosure
Y-MABS THERAPEUTICS INC
Common stock, par value $0.0001 per share · CUSIP: 984241109
Event date: 2025-08-14
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- ACORN BIOVENTURES, L.P.
Shares: 1,301,686.00 · Class: 3.0%
- ACORN CAPITAL ADVISORS GP, LLC
Shares: 1,301,686.00 · Class: 3.0%
- ACORN BIOVENTURES 2, L.P.
Shares: 1,794,611.00 · Class: 4.0%
- Acorn Capital Advisors GP 2, LLC
Shares: 1,794,611.00 · Class: 4.0%
- Anders Hove
Shares: 3,096,297.00 · Class: 7.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001636587-25-000045
- Form type
- SCHEDULE 13G/A
- Filer
- ACORN BIOVENTURES, L.P.
- CIK
- CIK 1766853
- Filed
- Aug 15, 2025
- Reporting period
- Aug 14, 2025
- Description
- Schedule 13G beneficial ownership